Dr. David Thomas Wenk, MD

Dr. Wenk practices at AdventHealth North Pinellas in Tarpon Springs, Florida, part of AdventHealth.

Dr. Wenk's NPI, 1508087297, was assigned on May 1, 2007. Dr. Wenk graduated from Ross University School of Medicine in 2004. Dr. Wenk holds Florida license ME98249.

Dr. Wenk's primary practice is AdventHealth North Pinellas, at 1395 S Pinellas Ave, Tarpon Springs, FL 34689 in Pinellas County. The practice phone is (813) 615-7219.

Dr. Wenk's primary practice is AdventHealth North Pinellas in Tarpon Springs, Florida, part of AdventHealth. Dr. Wenk is also affiliated with Morton Plant Hospital. The medical group on file is Florida Cancer Specialists & Research Institute. Dmand AI also links Dr. Wenk to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wenk practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Wenk's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Wenk is board certified in hematology by the American Board of Internal Medicine. Dr. Wenk is licensed in Florida.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, fluid and electrolyte imbalances, immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Wenk treats.

CMS data shows 119,915 Medicare services from Dr. Wenk across 44 procedure codes in 2024, for 942 Medicare patients. Medicare paid $2,912,868 for them.

CMS counts 942 Medicare patients who saw Dr. Wenk in 2024. The largest group is 75 to 84, with 405 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wenk's median patient age at 67, with 63% women.

In 2024, Dr. Wenk wrote 1,973 Medicare Part D claims for 414 patients. 81% of them were for generic drugs. CMS names the drug for 1,576 of them, across 41 drugs with 11 or more claims each, at $2,001,927 in total drug cost. In 2023, CMS named 1,893 claims across 54 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Wenk for performance year 2024, reported as part of a group. Dr. Wenk accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Wenk, published from 2017 to 2024. 2017 was the busiest year, with 2. Dr. Wenk's most frequent co-authors are Andrew Scott Kennedy, MD, Matthew Adam Fink, MD and Lucio Navarro Gordan, MD.

Dmand AI links Dr. Wenk to 1 clinical trial. Conditions studied include Waldenstrom Macroglobulinemia and Lymphoma, Mantle-Cell.

CMS Open Payments shows 1,249 general payments to Dr. Wenk from 88 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 68% of the total. Eli Lilly and Company paid the most, $57,293.

Dmand AI lists 1 award for Dr. Wenk, most recently CMS Stage 1 EHR in 2014.

Dr. Wenk graduated from Ross University School of Medicine in 2004.

Dr. Wenk is in network with 18 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.